|
[1]
|
Beck, L.H., Bonegio, R.G.B., Lambeau, G., Beck, D.M., Powell, D.W., Cummins, T.D., et al. (2009) M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 361, 11-21. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Debiec, H., Guigonis, V., Mougenot, B., Decobert, F., Haymann, J., et al. (2002) Antenatal Membranous Glomerulonephritis Due to Anti-Neutral Endopeptidase Antibodies. New England Journal of Medicine, 346, 2053-2060. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Pan, Y., Wan, J., Liu, Y., Yang, Q., Liang, W., Singhal, P.C., et al. (2014) Spla2 IB Induces Human Podocyte Apoptosis via the M-Type Phospholipase A2 Receptor. Scientific Reports, 4, Article No. 6660. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Pozdzik, A., Brochériou, I., David, C., Touzani, F., Goujon, J.M. and Wissing, K.M. (2018) Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. BioMed Research International, 2018, 1-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Sethi, S., Debiec, H., Madden, B., Charlesworth, M.C., Morelle, J., Gross, L., et al. (2020) Neural Epidermal Growth Factor-Like 1 Protein (NELL-1) Associated Membranous Nephropathy. Kidney International, 97, 163-174. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Sethi, S., Beck, L.H., Richard, J., et al. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. Mayo Clinic Proceedings, 98, 1671-1684.[CrossRef] [PubMed]
|
|
[7]
|
Jentzer, J.C., DeWald, T.A. and Hernandez, A.F. (2010) Combination of Loop Diuretics with Thiazide-Type Diuretics in Heart Failure. Journal of the American College of Cardiology, 56, 1527-1534.
|
|
[8]
|
Duffy, M., Jain, S., Harrell, N., Kothari, N. and Reddi, A.S. (2015) Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies. Cells, 4, 622-630. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276.
|
|
[11]
|
Dhaybi, O.A. and Bakris, G. (2017) Mineralocorticoid Antagonists in Chronic Kidney Disease. Current Opinion in Nephrology and Hypertension, 26, 50-55. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Parving, H., Brenner, B.M., McMurray, J.J.V., de Zeeuw, D., Haffner, S.M., Solomon, S.D., et al. (2012) Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 367, 2204-2213. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Agrawal, S., Zaritsky, J.J., Fornoni, A. and Smoyer, W.E. (2017) Dyslipidaemia in Nephrotic Syndrome: Mechanisms and Treatment. Nature Reviews Nephrology, 14, 57-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383, 1436-1446. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 388, 117-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ponticelli, C. and Podestà, M.A. (2020) Calcineurin Inhibitors in Lupus Nephritis. Journal of Nephrology, 34, 399-402. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
De Vriese, A.S., Glassock, R.J., Nath, K.A., et al. (2017) A Proposal for Aserology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology, 28, 421-430. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Reddy, V., Dahal, L.N., Cragg, M.S. and Leandro, M. (2016) Optimising B-Cell Depletion in Autoimmune Disease: Is Obinutuzumab the Answer? Drug Discovery Today, 21, 1330-1338. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Goede, V., Klein, C. and Stilgenbauer, S. (2015) Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment, 38, 185-192. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Reddy, V., Klein, C., Isenberg, D.A., Glennie, M.J., Cambridge, G., Cragg, M.S., et al. (2017) Obinutuzumab Induces Superior B-Cell Cytotoxicity to Rituximab in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patient Samples. Rheumatology, 56, 1227-1237. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Sethi, S., Kumar, S., Lim, K. and Jordan, S.C. (2020) Obinutuzumab Is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney International Reports, 5, 1515-1518. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Klomjit, N., Fervenza, F.C. and Zand, L. (2020) Successful Treatment of Patients with Refractory Pla2r-Associated Membranous Nephropathy with Obinutuzumab: A Report of 3 Cases. American Journal of Kidney Diseases, 76, 883-888. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G.J., Parren, P.W.H.I., et al. (2009) Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX. The Journal of Immunology, 183, 749-758. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Podestà, M.A., Ruggiero, B., Remuzzi, G. and Ruggenenti, P. (2020) Ofatumumab for Multirelapsing Membranous Nephropathy Complicated by Rituximab-Induced Serum-sickness. BMJ Case Reports, 13, e232896. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Jordan, N. and D’Cruz, D.P. (2014) Belimumab for the Treatment of Systemic Lupus Erythematosus. Expert Review of Clinical Immunology, 11, 195-204. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., et al. (2022) Anti CD38 Monoclonal Antibodies for Multiple Myeloma Treatment. Human Vaccines & Immunotherapeutics, 18, Article ID: 2052658. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Hartono, C., Chung, M., Kuo, S.F., Seshan, S.V. and Muthukumar, T. (2014) Bortezomib Therapy for Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy. Journal of Nephrology, 27, 103-106. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Geara, A.S., Bhoj, V. and Hogan, J.J. (2021) Bortezomib Treatment for Refractory Pla2r-Positive Membranous Nephropathy. Glomerular Diseases, 1, 40-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Salhi, S., Ribes, D., Colombat, M., Fortenfant, F. and Faguer, S. (2021) Bortezomib Plus Dexamethasone for Rituximab-Resistant PLA2R+ Membranous Nephropathy. Kidney International, 100, 708-709. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Arghiani, M., Zamani, B.H., Nazemian, F., Samadi, S., Afsharian, M.S., Habibzadeh, M., et al. (2021) A Cohort Study of Membranous Nephropathy, Primary or Secondary. BMC Nephrology, 22, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Caza, T.N., Hassen, S.I., Dvanajscak, Z., Kuperman, M., Edmondson, R., Herzog, C., et al. (2021) NELL1 Is a Target Antigen in Malignancy-Associated Membranous Nephropathy. Kidney International, 99, 967-976. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Ohtani, H., Wakui, H., Komatsuda, A., Okuyama, S., Masai, R., Maki, N., et al. (2004) Distribution of Glomerular Igg Subclass Deposits in Malignancy-Associated Membranous Nephropathy. Nephrology Dialysis Transplantation, 19, 574-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Yeo, M., Kim, Y.H., Choi, D.E., Choi, S., Kim, K. and Suh, K. (2018) The Usefulness of Phospholipase A2 Receptor and Igg4 Detection in Differentiation Primary Membranous Nephropathy from Secondary Membranous Nephropathy in Renal Biopsy. Applied Immunohistochemistry & Molecular Morphology, 26, 591-598. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Moroni, G. and Ponticelli, C. (2020) Secondary Membranous Nephropathy. A Narrative Review. Frontiers in Medicine, 7, Article 611317. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Morimoto, N., Nagahama, K., Tsuura, Y., Terai, A., Tanabe, M., Otani, M., et al. (2021) Membranous Nephropathy in a Patient with Pulmonary Tuberculosis Infection and Lung Adenocarcinoma: A Case Report. CEN Case Reports, 11, 126-133. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kaneko, T., Shimizu, A., Aoki, M. and Tsuruoka, S. (2014) A Case of Gefitinib-Associated Membranous Nephropathy in Treatment for Pulmonary Adenocarcinoma. CEN Case Reports, 4, 31-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Ratanasrimetha, P., Reddy, V.D., Kala, J., Tchakarov, A., Glass, W.F., Msaouel, P., et al. (2022) Case Report: Successful Treatment of Late-Onset Immune Checkpoint Inhibitor-Associated Membranous Nephropathy in a Patient with Advanced Renal Cell Carcinoma. Frontiers in Immunology, 13, Article 898811. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Pathak, N., Gunasekaran, I., Ambriose, M. and Nanda, S. (2022) Nell1 as Target Antigen for Mercury Related Membranous Nephropathy: A Case Report. Indian Journal of Nephrology, 32, 502-505.
|
|
[39]
|
Sewaralthahab, K., Rennke, H., Sewaralthahab, S., Madias, N.E. and Jaber, B.L. (2014) Potential Association between Membranous Nephropathy and Sargramostim Therapy for Pulmonary Alveolar Proteinosis. Clinical Nephrology–Case Studies, 3, 31-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Dauvergne, M., Moktefi, A., Rabant, M., Vigneau, C., Kofman, T., Burtey, S., et al. (2015) Membranous Nephropathy Associated with Immunological Disorder-Related Liver Disease. Medicine, 94, e1243. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Chen, R., Li, F., Xie, Q., Xue, J., Lai, L., Liu, S., et al. (2017) Membranous Nephropathy in a Patient with Ankylosing Spondylitis. Medicine, 96, e8201. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Moniwa, N., Shioya, Y., Gocho, Y., Takahashi, S., Tanaka, M., Furuhashi, M., et al. (2022) A Case of Membranous Nephropathy Secondary to Asymptomatic Graves’ Disease. CEN Case Reports, 11, 309-313. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Neves, P.D.M.d.M., Muniz, M.P.R., Morgantetti, G.F., Cutrim, É.M.M., Macieira, C.d.A., Salgado-Filho, N., et al. (2022) Membranous Nephropathy Secondary to Graves’ Disease: A Case Report. Frontiers in Immunology, 13, Article 824124. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Shima, Y., Nakanishi, K., Togawa, H., Obana, M., Sako, M., Miyawaki, M., et al. (2009) Membranous Nephropathy Associated with Thyroid-Peroxidase Antigen. Pediatric Nephrology, 24, 605-608. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Hanna, R.M., Arman, F., Selamet, U., Wallace, W.D., Barsoum, M., Rastogi, A., et al. (2019) Secondary Membranous Nephropathy in a Patient with Myasthenia Gravis without Thymic Disease, and Partial Remission Induced by Adrenocorticotropic Hormone Therapy. SAGE Open Medical Case Reports, 7, 2050313X1986976. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Pestana, N., Vida, C., Vieira, P., Durães, J. and Silva, G. (2021) Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report. Cureus, 13, 13-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Matsunaga, T. (2013) Membranous Glomerulonephritis Associated with Mycobacterium Shimoidei Pulmonary Infection. American Journal of Case Reports, 14, 543-547. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Balwani, M.R., Kute, V.B., Shah, P.R., Shah, M., Shinde, S.G., Shah, J. and Trivedi, H.L. (2016) Hepatitis B Viremia Manifesting as Polyarteritis Nodosa and Secondary Membranous Nephropathy. Journal of Nephropharmacology, 5, 119-121.
|
|
[49]
|
Inayat, F., Almas, T., Bokhari, S.R.A., Muhammad, A. and Sharshir, M.A. (2020) Membranous Glomerulonephritis as an Uncommon Presentation of Secondary Syphilis: A Reminder on Therapeutic Decision-Making in Clinical Practice. Journal of Investigative Medicine High Impact Case Reports, 8, 1-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Zhang, Z., Hever, A., Bhasin, N. and Kujubu, D.A. (2018) Secondary Syphilis Associated with Membranous Nephropathy and Acute Hepatitis in a Patient with HIV: A Case Report. The Permanente Journal, 22, 17-062. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Tang, K., Tseng, C., Hsieh, T. and Chen, D. (2018) Induction Therapy for Membranous Lupus Nephritis: A Systematic Review and Network Meta-Analysis. International Journal of Rheumatic Diseases, 21, 1163-1172. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Zilberman, T., Zahavi, T., Osadchy, A., Nacasch, N. and Korzets, Z. (2014) Membranous Nephropathy Associated with Sarcoidosis: A Primary or Secondary Glomerulopathy? The Israel Medical Association Journal, 16, 390-392.
|
|
[53]
|
Radhakrishnan, Y., Zand, L., Sethi, S. and Fervenza, F.C. (2024) Membranous Nephropathy Treatment Standard. Nephrology Dialysis Transplantation, 39, 403-413. [Google Scholar] [CrossRef] [PubMed]
|